All
FDA accepts new drug application for tazarotene lotion
August 19th 2019The U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for Ortho Dermatologics’ novel tazarotene O.045% lotion (IDP-123) with a PDUFA action date of Dec. 22, 2019, according a recent announcement from the company.
Powerful immunosuppressant agents predispose patients to fungal infections
July 26th 2019Patients on powerful immunocompromising agents might be predisposed to infections; however the potential association between biologic agents and increased risk isn’t necessarily universal, Whitney High, M.D., reported during the summer meeting of the American Academy of Dermatology.
Considerations before ordering genetic tests
July 15th 2019Recognize whether the test being ordered is the right one for the condition suspected, as well as whether the patient’s insurance company will fund it, Jennifer Hand, M.D., told colleagues at the Society for Pediatric Dermatology Annual Meeting this weekend in Austin, Texas.